Singapore temporarily halts use of two flu vaccines after South Korea deaths

No deaths associated with influenza vaccination have been reported in Singapore to date.

October 26, 2020 06:58 am | Updated 07:17 am IST - SINGAPORE

File photo for representation.

File photo for representation.

Singapore has temporarily halted the use of two influenza vaccines as a precaution after some people who received them in South Korea died, becoming among the first countries to publicly announce a halt of the vaccines' usage.

South Korea reported that 48 have died as of Saturday after getting flu shots, but said it would carry on with the state-run vaccination programme as they found no direct link between the deaths and the shots.

No deaths associated with influenza vaccination have been reported in Singapore to date, but the decision to halt the use of SKYCellflu Quadrivalent and VaxigripTetra was precautionary, the health ministry and the Health Sciences Authority (HAS) said in a statement late on Sunday.

The HSA is in touch with the South Korean authorities for further information as they investigate to determine if the deaths are related to influenza vaccinations.

SKYCellflu Quadrivalent is manufactured by South Korea's SK Bioscience and locally distributed by AJ Biologics, while VaxigripTetra is manufactured by Sanofi and locally distributed by Sanofi Aventis.

Two other influenza vaccines that have been brought into Singapore for the Northern Hemisphere 2020/21 influenza season may continue to be used, Singapore health authorities said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.